Second line antiretroviral therapy for treatment of HIV in Asia

1. Towards universal acess: scaling up priority HIV/AIDS interventions in the health sector: progress report. 2009. Geneva: WHO, UNAIDS, UNICEF.Search in Google Scholar

2. Renaud-Thery F, Nguimfack BD, Vitoria M, Lee E, Graaff P, et al. Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens. AIDS. 2007; 21(Suppl 4): S89-S95.10.1097/01.aids.0000279711.54922.f0Open DOISearch in Google Scholar

3. Orrell C, Harling G, Lawn SD, Kaplan R, McNally M, Bekker LG, et al. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. AntivirTher. 2007; 12: 83-8.10.1177/135965350701200106Search in Google Scholar

4. Kantor R, Diero L, Delong A, Kamle L, Muyonga S, Mambo F, et al. Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis. 2009; 49: 454-62.10.1086/600396Search in Google Scholar

5. Mee P, Fielding KL, Charalambous S, Churchyard GJ, Grant AD (2008) Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS. 22: 1971-7.10.1097/QAD.0b013e32830e4cd8Search in Google Scholar

6. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W, et al. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixeddose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis. 2007; 44: 447-52.10.1086/510745Search in Google Scholar

7. Hosseinipour MC, van Oosterhout JJ, Weigel R, Phiri S, Kamwendo D, Parkin N, et al. The public health approach to identify antiretroviral therapy failure: highlevel nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS. 2009; 23:1127-34.10.1097/QAD.0b013e32832ac34eOpen DOISearch in Google Scholar

8. Marcelin AG, Jarrousse B, Derache A, Ba M, Dakouo ML, Doumbia A, et al. HIV drug resistance after the use of generic fixed-dose combination stavudine/lamivudine/nevirapine as standard first-line regimen. AIDS. 2007; 21: 2341-3.10.1097/QAD.0b013e328235a527Search in Google Scholar

9. DHHS panel on clinical practices for treatment of HIV infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington DC:US Department of Health and Human Services, 2009. Search in Google Scholar

10. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. Geneva:World Health Organization. 2009.Search in Google Scholar

11. DHHS panel on clinical practices for treatment of HIV infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington DC: US Department of Health and Human Services. 2008.Search in Google Scholar

12. Gupta RK, Hill A, Sawyer AW, Cozzi-Lepri A, von Wyl V, Yerly S, et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis. 2009; 9: 409-17.10.1016/S1473-3099(09)70136-7Search in Google Scholar

13. Elliott JH, Lynen L, Calmy A, De Luca A, Shafer RW, Shafer RW, et al. Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching. AIDS. 2008; 22: 2053-67.10.1097/QAD.0b013e328309520d18753937Open DOISearch in Google Scholar

14. Youle M. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. JAntimicrobChemother. 2007; 60: 1195-205.10.1093/jac/dkm36417890281Search in Google Scholar

15. Pulido F, Arribas JR, Delgado R, Cabrero E, Gonzalez- Garcia J, Perez-Elias MJ, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS. 2008; 22: F1-9.10.1097/QAD.0b013e3282f4243bOpen DOISearch in Google Scholar

16. Delfraissy JF, Flandre P, Delaugerre C, Ghosn J, Horban A, Girard PM, et al. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviralnaive HIV-infected patients. AIDS. 2008; 22: 385-93.10.1097/QAD.0b013e3282f3f16dOpen DOISearch in Google Scholar

17. de Mendoza C, Valer L, Ribera E, Barreiro P, Martin- Carbonero L, Ramirez G, et al. Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIVinfected patients. HIV Clin Trials. 2006; 7:163-71.10.1310/hct0704-163Search in Google Scholar

18. Murphy R, da Silva B, Hicks C, Eron J, Gulick R, Thompson MA, et al. Seven-Year Efficacy of a Lopinavir/Ritonavir-Based Regimen in Antiretroviral- Naïve HIV-1-Infected Patients. HIV Clinical Trials. 2008; 9:1-10.10.1310/hct0901-1Search in Google Scholar

19. Ferradini L, Segeral O, Nouhin J, Leakhena S, Vara O, Dulioust A, et al. Efficacy of Kaletra-based secondline ART in Cambodia. Preceedings of the 14th Conference on Retrovirus and Opportunistic Infections (February, 2007, Los Angeles).Search in Google Scholar

20. Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS. 2006; 20: 711-8.10.1097/01.aids.0000216371.76689.63Open DOISearch in Google Scholar

21. Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, et al; CASTLE Study Team. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir,each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008; 372:646-55.10.1016/S0140-6736(08)61081-8Search in Google Scholar

22. Cohen C, Nieto-Cisneros L, Zala C, Fessel WJ, Gonzalez-Garcia J, Gladysz A, et al. Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial. Curr Med Res Opin. 2005; 21: 1683-92.10.1185/030079905X65439Search in Google Scholar

23. Malan DR, Krantz E, David N, Wirtz V, Hammond J, McGrath D, 089Study Group. Efficacy and safety of atazanavir, with or without ritonavir, as part of oncedaily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J Acquir Immun Defic Syndr. JAIDS. 2008; 47: 161-7.Search in Google Scholar

24. Bierman WF, van Agtmael MA, Nijhuis M, Danner SA, Boucher CA. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS. 2009; 23: 279-91.10.1097/QAD.0b013e32831c54e519114854Open DOISearch in Google Scholar

25. Hellinger J, Cohen C, Morris A, Sheble-Hall S, Gordon D, Foy C, et al. Pilot study of saquinavir and lopinavir/ ritonavir twice daily in protease inhibitor-naive HIVpositive patients. HIV Clin Trials. 2005; 6: 107-17.10.1310/YGKE-7K4V-UF5R-4F1G15983895Search in Google Scholar

26. Staszewski S, Babacan E, Stephan C, Haberl A, Carlebach A, Gute P, et al. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy. J AntimicrobChemother. 2006; 58: 1024-30.10.1093/jac/dkl37516956902Search in Google Scholar

27. Ribera E, Azuaje C, Lopez RM, Diaz M, Feijoo M, Pou L, et al. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen. AIDS. 2006. 20: 1131-9.10.1097/01.aids.0000226953.56976.ad16691064Search in Google Scholar

28. Chetchotisakd P, Anunnatsiri S, Mootsikapun P, Kiertiburanakul S, Anekthananon T, Bowonatanuwong C, et al. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors. HIV Medicine. 2007; 8: 529-35.10.1111/j.1468-1293.2007.00506.x17944686Search in Google Scholar

29. Tenore S, Ferreira PA, Diaz RS. Saquinavir plus lopinavir/ritonavir versus amprenavir plus lopinavir/ ritonavir for treating highly resistant patients in Brazil. J Acquir Immune Defic Syndr. 2008; 47: 526-28.10.1097/QAI.0b013e31815b0d6f18332770Search in Google Scholar

30. Manosuthi W, Sungkanuparph S, Ruxrungtham K, Prasithsirikul W, Athichathanabadi C, Tantisiriwat W, et al. Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir. J Acquir Immune Defic Syndr. 2008; 47: 127-9.10.1097/QAI.0b013e318157b0da236591218156991Search in Google Scholar